Biology of Cancer - Cancer Currents Blog
Cancer biology research news, with context from experts at NCI and elsewhere. Topics include cancer metastasis, the tumor microenvironment, and new targets for cancer therapies.
-
In people with cancer treated with immune checkpoint inhibitors, a rare, but often fatal, side effect is inflammation in the heart, called myocarditis. Researchers have now identified a potential chief cause of this problem: T cells attacking a protein in heart cells called α-myosin.
-
A new study suggests that people with obesity who had bariatric surgery had a much lower risk of five common cancers that aren’t related to hormone levels, including lung, colorectal, and esophageal cancer.
-
In a new study, researchers showed that cancer cells with mutations in the IDH1 gene release large amounts of a metabolite called D-2HG. Once outside of the cells, D-2HG acts like force field by neutralizing nearby immune cells.
-
Cisplatin raises levels of a fat molecule called S1P in areas of the brain responsible for memory and information processing, a new study shows. S1P locks onto a protein on the surface of brain cells called S1PR1. In mice given cisplatin, drugs that block S1PR1 prevented cognitive problems.
-
Two research teams have developed a treatment approach that could potentially enable KRAS-targeted drugs—and perhaps other targeted cancer drugs—flag cancer cells for the immune system. In lab studies, the teams paired these targeted drugs with experimental antibody drugs that helped the immune system mount an attack.
-
Two companion studies have found different forms of some brain tumors, diffuse midline glioma and IDH-mutant glioma, become dependent for their survival on the production of chemicals called pyrimidines. Clinical trials are planned to test a drug that blocks pyrimidine synthesis in patients with gliomas.
-
Abnormal collagen that is formed only by pancreatic cancer cells ramps up activity that increases tumor growth and survival, a study found. In mice, blocking production or effects of the abnormal collagen made treatment for pancreatic cancer more effective.
-
Inflammation is considered a hallmark of cancer. Researchers hope to learn more about whether people with cancer might benefit from treatments that target inflammation around tumors. Some early studies have yielded promising results and more are on the horizon.
-
The fusion protein that drives the growth and survival of some rhabdomyosarcoma tumors relies on the KDM4B enzyme, researchers have found. Treating mice with a KDM4B-blocking drug and chemotherapy nearly eliminated rhabdomyosarcoma tumors with the fusion protein.
-
A research team hopes to offer oncologists a new tool to guide treatment choices for their patients. In a small study, a tumor model called micro-organospheres accurately predicted whether patients would respond to their chemotherapy treatment.